The benefit of chemotherapy among women with early-stage, hormone-receptor positive breast cancers has become largely determinant on the use of gene expression profiles, including Oncotype DX, MammaPrint, and PAM50. Oncotype DX score is a 21-gene assay that uses RT-PCR to calculate recurrence risk using a scoring system from 0 to 100, and categorizes women into low, intermediate, and high risk of recurrence based on pre-specified cut points. MammaPrint is a 70-gene assay performed with microarray, and classifies tumors as having good vs poor prognostic signatures. PAM50 tests 50 classifier genes and categorizes women by intrinsic subtypes including luminal A, luminal B, HER2-enriched, basal-like and normal-like. Adjuvant! Online is an online program that uses standard clinicopathologic variables to estimate survival for breast cancer patients treated by local therapy alone and the survival and disease-free survival benefit gained by the addition of systemic adjuvant therapy.
Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016. View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO